蛋白质组学分析揭示肥厚型心肌病的高危分子亚型
本研究对258例肥厚型心肌病患者进行血浆蛋白质组学检测(1681种蛋白),采用无监督机器学习识别出四种分子亚型,中位随访2.8年。四种亚型无主要不良心血管事件生存率存在显著差异(plogrank=0.007),D亚型风险最高(HR 3.41,95%CI 1.54-7.55,p=0.003),其差异蛋白富集于Ras/MAPK、炎症和纤维化通路。
要点
- 血浆蛋白质组学可识别肥厚型心肌病的四种分子亚型,各亚型预后显著不同。
- D亚型患者主要不良心血管事件风险显著高于A亚型(HR 3.41,95%CI 1.54-7.55)。
- D亚型差异蛋白富集于Ras/MAPK、炎症及纤维化相关通路。
核心结论
- 肥厚型心肌病存在四种分子亚型,其中D亚型为高危亚型,与Ras/MAPK及炎症纤维化通路上调相关。
研究设计与样本
- 多中心前瞻性队列研究,纳入258例肥厚型心肌病患者,检测血浆1681种蛋白,中位随访2.8年。
主要发现
- 四种分子亚型间无主要不良心血管事件生存率差异显著(plogrank=0.007)。
- D亚型主要不良心血管事件风险显著高于A亚型(HR 3.41,95%CI 1.54-7.55,p=0.003)。
关键数值与推荐
- 主要不良心血管事件定义为心律失常、心力衰竭、卒中和心源性猝死的复合终点。
临床怎么用
- 血浆蛋白质组学有望用于肥厚型心肌病风险分层,识别高危D亚型患者以加强管理。
局限性
- 样本量258例,中位随访2.8年,分子亚型的临床可操作性需外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Hypertrophic cardiomyopathy (HCM) is a heterogeneous disease, likely encompassing several subtypes of disease with distinct biological mechanisms (ie, molecular subtypes). Current models based solely on clinical data have yielded limited accuracy in predicting the risk of major adverse cardiovascular events (MACE). Our aim in this study was to derive molecular subtypes in our multicentre prospective cohort of patients with HCM using proteomics profiling and to examine their longitudinal associations with MACE. METHODS: We applied unsupervised machine learning methods to plasma proteomics profiling data of 1681 proteins from 258 patients with HCM who were prospectively followed for a median of 2.8 years. The primary outcome was MACE, defined as a composite of arrhythmia, heart failure, stroke and sudden cardiac death. RESULTS: We identified four molecular subtypes of HCM. Time-to-event analysis revealed significant differences in MACE-free survival among the four molecular subtypes (plogrank=0.007). Compared with the reference group with the lowest risk of MACE (molecular subtype A), patients in molecular subtype D had a higher risk of subsequently developing MACE, with an HR of 3.41 (95% CI 1.54 to 7.55, p=0.003). Pathway analysis of proteins differentially regulated in molecular subtype D demonstrated an upregulation of the Ras/mitogen-activated protein kinase and associated pathways, as well as pathways related to inflammation and fibrosis (eg, transforming growth factor-β pathway). CONCLUSIONS: Our prospective plasma proteomics study not only exhibited the presence of HCM molecular subtypes but also identified pathobiological mechanisms associated with a distinct high-risk subtype of HCM.
引用
- Liang LW, Raita Y, Hasegawa K, et al. Proteomics profiling reveals a distinct high-risk molecular subtype of hypertrophic cardiomyopathy. Heart. 2022. PMID: 35351822. doi:10.1136/heartjnl-2021-320729
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。